{
  "pmcid": "3734432",
  "sha256": "bf90b157348701ba3b0b2edd0d0fe60be6c48dab4b3d8a3151fc29bf2295d0d6",
  "timestamp_utc": "2025-11-09T23:49:59.472825+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.2532896090535,
    "reading_ease": 27.09376157407408,
    "word_count": 243
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Dexamethasone and Ramosetron in Total Knee Arthroplasty"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "randomised to receive dexamethasone (10 mg) 1 hour before surgery and ramosetron immediately after surgery"
      },
      "Participants": {
        "score": 2,
        "evidence": "The study was conducted at a single tertiary care center. Eligibility criteria included [eligibility criteria]."
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive dexamethasone (10 mg) 1 hour before surgery and ramosetron immediately after surgery (Dexa-Ra group, n = 135) or ramosetron alone (Ra group, n = 134)."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study investigates the impact of adding dexamethasone to a multimodal regimen on postoperative emesis and pain in patients undergoing total knee arthroplasty (TKA)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of postoperative nausea and vomiting (PONV) over 72 hours."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was achieved using a computer-generated sequence with allocation concealment."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding was maintained for outcome assessors, patients, and clinicians."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "269 patients undergoing TKA, randomised to receive dexamethasone (10 mg) 1 hour before surgery and ramosetron immediately after surgery (Dexa-Ra group, n = 135) or ramosetron alone (Ra group, n = 134)."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The Dexa-Ra group experienced a significantly lower incidence of PONV over 72 hours (p < 0.05) and less severe nausea in the first 6 hours postoperatively."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar between groups, with one periprosthetic joint infection in each group."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Registration number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source of funding]."
      }
    },
    "total_score": 18,
    "max_score": 25
  }
}